AUPH Aurinia Pharmaceuticals Inc.
Price Chart
Executive Summary
Aurinia CEO Kevin Tang made a conviction buy of ~552K shares (~$8.4M in open-market purchases) over three days, with bulk of buying at $15.28 on June 1-2. This represents ~0.4% of the $2.1B market cap — a material, proportionally meaningful insider buy from the company's top executive. The purchase is inconsistent with diversification or 10b5-1 pattern and signals the CEO's view that the stock is undervalued at current levels.
Key Financial Metrics
Actionable Insight
CEO Tang's concentrated $8.4M buy near multi-week lows (mid-$15s) is a strong, standalone conviction signal. Monitor for a concurrent or upcoming corporate catalyst (e.g., pipeline milestone, NDA filing, or strategic update) that could explain the timing. If stock trades below Tang's average entry price (~$15.28) without new adverse news, the insider purchase pattern suggests accumulation opportunity for long-side traders.
Key Facts
- CEO Kevin Tang purchased ~552K shares for ~$8.4M over May 29–June 2, 2026
- Largest single-day purchase was 343.5K shares at $15.28 on June 1 (~$5.3M)
- Purchases represent ~0.4% of the company's $2.1B market cap
- CEO acts as the sole insider buyer — no other insider sold or bought during the window
- No identified 10b5-1 pattern; purchases clustered over consecutive trading days at near-identical prices
Financial Impact
$8.4M in open-market CEO stock purchases (~0.4% of market cap)
Risk Factors
- Biotech sector risk; single-asset / single-pipeline reliance may drive stock price independent of insider views
- Insider buys material by dollar value but represent <0.5% of market cap — not transformative on its own
- No additional C-suite or board buys to confirm shared conviction; lone-CEO buy could be personal conviction not shared by wider management
- Historical calibration shows segment score-6 filings have only 34% observed win rate at T+20, though mean win alpha is +14.9% versus mean loss alpha of -15.6%
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | AUPH-1780949450182 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
7d ago
|
Insider Buy
| $15.39 awaiting T+5 | awaiting T+5 | — | $15.66 (+1.75%) |
|
May 11, 2026
29d ago
|
8-K
| $15.72 $15.60 | ▼ −0.76% | ▼ −0.68% | $15.66 (−0.38%) |
|
Feb 26, 2026
14w ago
|
8-K
| $13.97 $14.74 | ▲ +5.51% | ▲ +6.64% | $15.66 (+12.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access